PRMT5 as a druggable target for glioblastoma therapy

Yeshavanth Kumar Banasavadi-Siddegowda, Alessandra M. Welker, Min An, Xiaozhi Yang, Wei Zhou, Guqin Shi, Jaime Imitola, Chenglong Li, Sigmund Hsu, Jiang Wang, Mitch Phelps, Jianying Zhang, Christine E. Beattie, Robert Baiocchi, Balveen Kaur

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Background In spite of standard multimodal therapy consisting of surgical resection followed by radiation and concurrent chemotherapy, prognosis for glioblastoma (GBM) patients remains poor. The identification of both differentiated and undifferentiated "stem cell like" populations in the tumor highlights the significance of finding novel targets that affect the heterogeneous tumor cell population. Protein arginine methyltransferase 5 (PRMT5) is one such candidate gene whose nuclear expression correlates with poor survival and has been reported to be required for survival of differentiated GBM cells and self-renewal of undifferentiated GBM cells. In the current study we screened the specificity and efficacy of 4 novel PRMT5 inhibitors in the treatment of GBM. Methods Efficacies of these inhibitors were screened using an in vitro GBM neurosphere model and an in vivo intracranial zebrafish model of glioma. Standard molecular biology methods were employed to investigate changes in cell cycle, growth, and senescence. Results In vitro and in vivo studies revealed that among the 4 PRMT5 inhibitors, treatment of GBM cells with compound 5 (CMP5) mirrored the effects of PRMT5 knockdown wherein it led to apoptosis of differentiated GBM cells and drove undifferentiated primary patient derived GBM cells into a nonreplicative senescent state. Conclusion In vivo antitumor efficacy combined with the specificity of CMP5 underscores the importance of developing it for translation.

Original languageEnglish (US)
Pages (from-to)753-763
Number of pages11
Issue number6
StatePublished - May 18 2018
Externally publishedYes


  • CMP5
  • GBM
  • PRMT5
  • glioma
  • senescence

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'PRMT5 as a druggable target for glioblastoma therapy'. Together they form a unique fingerprint.

Cite this